TD Waterhouse Canada »

Adaptimmune Therapeutics shares owned by TD Waterhouse Canada

Quarter-by-quarter ownership of Adaptimmune Therapeutics (ADAP) shares owned by TD Waterhouse Canada from 13F filings

Historical chart of TD Waterhouse Canada investment in Adaptimmune Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Adaptimmune Therapeutics held by TD Waterhouse Canada consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Adaptimmune Therapeutics by TD Waterhouse Canada

Quarter filed Position value Share count Share price at filing
2024-09-30 $13 14 0.93

More positions owned by TD Waterhouse Canada

Rbc Cad (RY)
Toronto Dominion Bk Ont Com New (TD)
Microsoft Corporation (MSFT)
Apple (AAPL)
Enbridge (ENB)
Bank Of Montreal Cadcom (BMO)
Manulife Finl Corp (MFC)
Tc Energy Corp (TRP)
Canadian Natural Resources (CNQ)
Canadian Natl Ry (CNI)
Brookfield Corp Cl A Ltd Vt Sh (BN)
JPMorgan Chase & Co. (JPM)
Fortis (FTS)
Amazon (AMZN)
Spdr S&p 500 Etf Tr Tr Unit (SPY)

View all positions for TD Waterhouse Canada

Top funds holding Adaptimmune Therapeutics

EcoR1 Capital
NEA Management Company
Two Seas Capital
Long Focus Capital Management
Baillie Gifford & Co
MPM Asset Management
MPM Oncology Impact Management
Partner Fund Management
Bank of America Corporation
Renaissance Technologies
Rock Springs Capital Management
FMR
Morgan Stanley
Jpmorgan Chase & Co
Redmile Group

View all funds holding Adaptimmune Therapeutics